360 related articles for article (PubMed ID: 26243202)
1. American Association of Cancer Research Showcases Immunotherapy Advances.
Brower V
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26243202
[No Abstract] [Full Text] [Related]
2. PD-1-targeted immunotherapy: recent clinical findings.
Brahmer JR
Clin Adv Hematol Oncol; 2012 Oct; 10(10):674-5. PubMed ID: 23187774
[No Abstract] [Full Text] [Related]
3. Challenges to Biomarker Testing for PD-1/PD-L1 Checkpoint Inhibitors for Lung Cancer.
Cagle PT; Bernicker EH
Arch Pathol Lab Med; 2015 Dec; 139(12):1477-8. PubMed ID: 26619015
[No Abstract] [Full Text] [Related]
4. Clinical Trials of PD-1 and PD-L1 inhibitors in NSCLC.
Clin Adv Hematol Oncol; 2014 Jan; 12(1 Suppl 1):14-6. PubMed ID: 24852398
[No Abstract] [Full Text] [Related]
5. Immuno-oncology moves beyond PD-1.
Sheridan C
Nat Biotechnol; 2015 Jul; 33(7):673-5. PubMed ID: 26153987
[No Abstract] [Full Text] [Related]
6. PD-1 Blockers.
Wolchok JD
Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
[TBL] [Abstract][Full Text] [Related]
7. Immuno-oncology drugs jostle for first-line setting.
Mullard A
Nat Rev Drug Discov; 2016 Nov; 15(11):738. PubMed ID: 27807351
[No Abstract] [Full Text] [Related]
8. Programmed death protein 1 inhibitors making inroads in multiple cancers.
Brower V
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957444
[No Abstract] [Full Text] [Related]
9. Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.
Hersey P; Gowrishankar K
Future Oncol; 2015; 11(1):133-40. PubMed ID: 25572788
[TBL] [Abstract][Full Text] [Related]
10. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Garon EB
Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
[TBL] [Abstract][Full Text] [Related]
11. Advances in Immuno-Oncology: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer-Introduction.
Socinski MA
Semin Oncol; 2015 Oct; 42 Suppl 2():S1-2. PubMed ID: 26477469
[No Abstract] [Full Text] [Related]
12. Immune modulation in cancer with antibodies.
Page DB; Postow MA; Callahan MK; Allison JP; Wolchok JD
Annu Rev Med; 2014; 65():185-202. PubMed ID: 24188664
[TBL] [Abstract][Full Text] [Related]
13. First-Line Immune Therapy-Implications for Pathologists.
Miller RA; Cagle PT; Bernicker EH
Arch Pathol Lab Med; 2016 Aug; 140(8):739-40. PubMed ID: 27472228
[No Abstract] [Full Text] [Related]
14. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
[TBL] [Abstract][Full Text] [Related]
15. PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges.
Lee J; Kefford R; Carlino M
Immunotherapy; 2016 Jun; 8(6):733-46. PubMed ID: 27197541
[TBL] [Abstract][Full Text] [Related]
16. Beyond ipilimumab: new approaches target the immunological synapse.
Garber K
J Natl Cancer Inst; 2011 Jul; 103(14):1079-82. PubMed ID: 21737695
[No Abstract] [Full Text] [Related]
17. Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies.
Robert C; Soria JC; Eggermont AM
Eur J Cancer; 2013 Sep; 49(14):2968-71. PubMed ID: 23907003
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression as a potential predictive biomarker.
Fusi A; Festino L; Botti G; Masucci G; Melero I; Lorigan P; Ascierto PA
Lancet Oncol; 2015 Oct; 16(13):1285-7. PubMed ID: 26433815
[No Abstract] [Full Text] [Related]
19. PD-1 and PD-L1 blockade in gastrointestinal malignancies.
Lote H; Cafferkey C; Chau I
Cancer Treat Rev; 2015 Dec; 41(10):893-903. PubMed ID: 26412280
[TBL] [Abstract][Full Text] [Related]
20. Promising early results for immunotherapy-antiangiogenesis combination.
Garber K
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25421345
[No Abstract] [Full Text] [Related]
[Next] [New Search]
